secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2023-08-04T23:59:59+00:00
Accession:  0001558370-23-013308
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KALA BIO Q2 net loss $10.4M; cash $59.2M; CHASE trial topline data expected Q2 2024
--------------------------------------------------------------------------------

- Net loss of $10.4M ($4.36/share) vs $28.1M ($18.92/share) in Q2 2022; operating loss $9.6M.
- Cash, equivalents and short-term investments $59.2M as of June 30, 2023; CIRM $15M grant extends runway into Q2 2025.
- CHASE Phase 2b trial for KPI-012 in PCED actively enrolling; topline data targeted for Q2 2024.
- No product revenue after sale of commercial portfolio to Alcon in July 2022; SG&A fell to $5.0M from $22.7M.
- Rebranded to KALA BIO from Kala Pharmaceuticals, reflecting focus on biologics for rare ophthalmic diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000155837023013308/0001558370-23-013308-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000155837023013308/kala-20230804x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-013308

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer